Meeting of the National Science Advisory Board for Biosecurity (NSABB)
Teleconference call only (No in-person meeting)
The toll-free teleconference meeting line will be open to the public at 11:30 A.M. to allow time for operator-assisted check-in.
This teleconference meeting is open to the public toll-free. Participants may pre-register online at http://palladianpartners.cvent.com/d/8vq19c or by contacting Ida Donner (Palladian Partners, Inc.) at 301–273–2838. Pre-registration closes at 12:00 P.M. Eastern on November 1, 2016. Participants may also register their information with the telephone operator upon dialing into the meeting.
Agenda and Materials
The meeting agenda and other materials will be posted to this page once available. Please visit this webpage for updates. Agenda items will include presentations and discussions regarding: (1) stakeholder engagement on implementation of the U.S. Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC); (2) status of the Blue Ribbon Panel review of the 2014 variola virus incident on the NIH Bethesda campus; and (3) other business of the Board.
Time will be allotted on the agenda for the delivery of public comments. Members of the public interested in delivering prepared comments relevant to the mission of the NSABB may indicate so upon registration. Sign-up for delivering prepared oral comments will be limited to one per person or organization representative per open comment period. Individual comments will be time-limited to facilitate broad participation from multiple speakers.
In addition, interested persons may file written comments at any time with the Board via an email sent to email@example.com or by regular mail sent to the Contact Person listed on this notice. Written statements should include the name, contact information, and when applicable, the professional affiliation of the interested person. Written comments received by 12:00 P.M. Eastern on November 1, 2016 will be relayed to the NSABB prior to the teleconference meeting. Any written comments received after this deadline will be provided to the Board either before or after the meeting, depending on the volume of comments received and the time required to process them in accordance with privacy regulations and other applicable federal policies.
Additional questions, please contact:
Christopher Viggiani, Ph.D.
Executive Director, NSABB
NIH Office of Science Policy
6705 Rockledge Drive, Suite 750
Bethesda, Maryland 20892